MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202521006535 A) filed by Stem Plus Biotech Pvt. Ltd. on January 27, 2025, for Synthesis Method Of Bioink For 3rd Printing Of Spinal Cord Grafts For Tissue Engineering And Clinical Applications.
Inventors include Dr. Meghnad Ganesh Joshi; Ms. Leena Rajendra Chaudhari; and Mr. Mahendra V Pacchapurkar.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: Abstract Spinal cord injuries (SCI) lead to permanent functional deficits as a consequence of neuronal tissue damage, which is marked by demyelination, loss of synapses, and degeneration of axons. SCI has a profound effect oil the physical, emotional, arid socioeconomic health of patients, exhibiting increased morbidity and mortality rates, especially in younger populations. The pathophysiological aspects of SCI encompass acute, sub-acute, and chronic stages, each of which poses distinct obstacles to natural recovery, including the formation of glial scars and Wallefian degeneration. Current treatments for SCI are either ineffective, complicated, or too expensive to administer, which makes it important to develop feasible and inexpensive remedies. Three-dimensional (3D) bioprinting is an emerging technology in regenerative medicine, creating biomimetic tissue constructs with the ability to engineer porosity, permeability, and mechanical properties in a precise manner. The current work invents a newly developed bioink for 3D bioprinting of spinal cord grafts. The bioink contains xenogenic or allogenic spinal cord extracellular matrix (ECM), polyvinyl alcohol (PVA), gelatin, and fibronectin. The ECM component promotes cell attachment, proliferation, and migration, whereas the synthetic polymers provide structural integrity, which closely mimics the biomechanical properties of native spinal cord tissue. The main goals are to generate spinal cord-specific ECM from allogenic or xenogenic sources to develop bioink, characterization of bioink properties using FTIR, TGA, and rheological analyses, and biocompatibility studies by in ovo and transplantation study in preclinical models. The fabricated grafts will be used to bridge the injured spinal cord gaps and stimulate regeneration and functional recovery. This bioink holds considerable promise for clinical use, such as personalized regenerative therapies, in vitro toxicology models, and foundational spinal cord preclinical research.
Disclaimer: Curated by HT Syndication.
